Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer clue: LKB1 gene may predict best therapy

NCT ID NCT07710599

Ongoing Knowledge-focused Sponsor: Ling Zhiqiang Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study examines whether changes in the LKB1 gene can help predict how well people with non-small cell lung cancer respond to treatments like chemotherapy, targeted therapy, and immunotherapy. Researchers will analyze tumor samples and medical records from about 300 patients to see if LKB1 status, along with other gene changes, is linked to survival and treatment outcomes. The goal is to improve personalized treatment choices for lung cancer patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a way to use LKB1 status to choose the best treatment for each person with non-small cell lung cancer.
What could go wrong
This is a retrospective study that looks at past data, so it cannot prove cause and effect. The results may not apply to all patients or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.